In the last trading session, 9.0 million Tango Therapeutics Inc (NASDAQ:TNGX) shares changed hands as the company’s beta touched 1.51. With the company’s per share price at $5.01 changed hands at $0.09 or 1.83% during last session, the market valuation stood at $543.05M. TNGX’s last price was a discount, traded about -139.92% off its 52-week high of $12.02. The share price had its 52-week low at $1.03, which suggests the last value was 79.44% up since then. When we look at Tango Therapeutics Inc’s average trading volume, we note the 10-day average is 3.56 million shares, with the 3-month average coming to 2.50 million.
Analysts gave the Tango Therapeutics Inc (TNGX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.12. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended TNGX as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Tango Therapeutics Inc’s EPS for the current quarter is expected to be -0.35.
Tango Therapeutics Inc (NASDAQ:TNGX) trade information
Instantly TNGX was in green as seen at the end of in last trading. With action -2.91%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -45.90%, with the 5-day performance at -2.91% in the red. However, in the 30-day time frame, Tango Therapeutics Inc (NASDAQ:TNGX) is 158.25% up. Looking at the short shares, we see there were 15.67 million shares sold at short interest cover period of 3.2 days.
The consensus price target for the stock as assigned by Wall Street analysts is 13, meaning bulls need an upside of 61.46% from its current market value. According to analyst projections, TNGX’s forecast low is 13 with 18 as the target high. To hit the forecast high, the stock’s price needs a -259.28% plunge from its current level, while the stock would need to soar -159.48% for it to hit the projected low.
Tango Therapeutics Inc (TNGX) estimates and forecasts
Year-over-year growth is forecast to reach -33.09% down from the last financial year.
Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of 6.42M. 7 analysts are of the opinion that Tango Therapeutics Inc’s revenue for the current quarter will be 6.48M. The company’s revenue for the corresponding quarters a year ago was 19.88M and 11.61M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -67.70%. The estimates for the next quarter sales put growth at -44.17%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 7.47%. The 2025 estimates are for Tango Therapeutics Inc earnings to decrease by -13.03%, but the outlook for the next 5-year period is at -5.61% per year.
TNGX Dividends
Tango Therapeutics Inc is expected to release its next quarterly earnings report on 2025-May-12.
Tango Therapeutics Inc (NASDAQ:TNGX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 12.59% of Tango Therapeutics Inc shares while 97.75% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 111.82%. There are 97.75% institutions holding the Tango Therapeutics Inc stock share, with TRV GP IV, LLC the top institutional holder. As of 2024-06-30, the company held 17.7276% of the shares, roughly 19.2 million TNGX shares worth $164.75 million.
ECOR1 CAPITAL, LLC holds the second largest percentage of outstanding shares, with 12.3075% or 13.33 million shares worth $114.38 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and T. Rowe Price Small-Cap Value Fund, Inc. . With 2.2 shares estimated at $11.04 million under it, the former controlled 2.03% of total outstanding shares. On the other hand, T. Rowe Price Small-Cap Value Fund, Inc. held about 1.53% of the shares, roughly 1.66 shares worth around $8.33 million.
